## Highlights of This Issue 3359

### SPECIAL FEATURES

#### CCR Translations

- **3361** MET as a Target in Papillary Renal Cell Carcinoma
  
  André P. Fay, Sabina Signoretti, and Toni K. Choueiri
  
  *See related article, p. 3411*

#### CCR Perspectives in Drug Approval

- **3364** U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009
  
  Sonia K. Morgan-Linnell, David J. Stewart, and Razelle Kurzrock

#### Statistics in Clinical Cancer Research

- **3371** Blocking and Randomization to Improve Molecular Biomarker Discovery
  
  Li-Xuan Qin, Qin Zhou, Faina Bogomolniy, Liliana Villafañia, Narciso Olvera, Magali Cavatore, Jaya M. Satagopan, Colin B. Begg, and Douglas A. Levine

#### Molecular Pathways

- **3379** Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
  
  Mark A. Dickson

- **3384** Molecular Pathways: Niches in Metastatic Dormancy
  
  Kenji Yumoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, and Yusuke Shiozawa

#### Review

- **3390** Infusions of Allogeneic Natural Killer Cells as Cancer Therapy
  
  Wing Leung

## HUMAN CANCER BIOLOGY

- **3401** Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
  
  Yong-Chen Lu, Xin Yao, Jessica S. Crystal, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yardena Samuels, Steven A. Rosenberg, and Paul F. Robbins

- **3411** MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
  
  Laurence Albige, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Campano, Zahara Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Cousé, Sophie Gad, Jean-Jacques Patard, and Bernard Escudier
  
  *See related article, p. 3361*

- **3422** Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer
  
  Natalie Hartmann, Nathalia A. Giese, Thomas Giese, Isabel Poschke, Rienk Oftringa, Jens Werner, and Eduard Ryschich

- **3434** Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer
  
  Hongyan Yu, Wen Ye, Jianguxue Wu, Xiangqi Meng, Ran-yi Liu, Xiaofang Ying, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

## CANCER THERAPY: PRECLINICAL

- **3446** Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
  
  Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cerniglia, Bjorn Titz, Thiliee Chodon, Thomas G. Graeber, Begonya Comín-Andúix, and Antoni Ribas
Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)  

Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis  
Dongshi Chen, Liang Wei, Jian Yu, and Lin Zhang

Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells  
Sae-Kyung Lee, Jyh Y. Chwee, Cheryl A.P. Ma, Nina Le Bert, Caleb W. Huang, and Stephan Gasser

Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage  
GiannariaLiccardi, John A. Hartley, and Daniel Hochhauser

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT  

Old Drug New Use—Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity  
Ren Kong, Timothy Liu, Xiaoping Zhu, Syed Ahmad, Alfred L. Williams, Alexandra T. Phan, Hong Zhao, John E. Scott, Li-An Yeh, and Stephen T.C. Wong

In Vivo Fluorescence Lifetime Imaging for Monitoring the Efficacy of the Cancer Treatment  
Yasaman Ardestirpour, Victor Chernomordik, Mohinuddin Hassan, Rafał Zielinski, Jacek Capala, and Amir Gandjbakhche

Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18F-Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study  
Katja Pinker, Wolfgang Bogner, Pascal Balthzer, Georgios Karanikas, Heinrich Magometschnig, Peter Brader, Stephan Gruber, Hubert Bickel, Peter Dusby, Zsuzsanna Bago-Horvath, Rupert Bartsch, Michael Weber, Siegfried Trattning, and Thomas H. Helbich

Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy  
Johannes Schwarzeneber, Johannes Cserni, Timothy F. Cloughesy, Benjamin M. Ellingson, Whitney B. Pope, Tristan Grogan, David Elashoff, Cheri Geist, Daniel H.S. Silverman, Michael E. Phelps, and Wei Chen

Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm  
Binsheng Zhao, Shing M. Lee, Hyun-Ju Lee, Yongqiang Tan, Jing Qi, Thorsten Persiehbl, David P. Mozley, and Lawrence H. Schwartz

TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance  
Laxmi Silwal-Pandit, Hans Kristian Moen Vollan, Suet-Feung Chin, Oscar M. Rueda, Steven McKinney, Tomo Osako, David A. Quigley, Vessela N. Kristensen, Samuel Aparicio, Anne-Lise Borresen-Dale, Carlos Celdus, and Anita Langerod

A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer  
Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eyas Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor Saleh, and Donald Thornton

Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q- Patients with MDS and AML  
Katharina Blatt, Harald Herrmann, Gregor Hoermann, Michael Willmann, Sabine Cerny-Reiterer, Irina Sadovnik, Susanne Herndlhöfer, Berthold Streubel, Werner Rabitsch, Wolfgang R. Sperr, Matthias Mayerhofer, Thomas Rülicke, and Peter Valent
LETTERS TO THE EDITOR

3623 SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti

3625 SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response
Qianxia Li, Huihua Xiong, and Xianglin Yuan

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

3613 Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Mikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, Mototsugu Shimokawa, Hirokazu Kitahara, Shinichiro Shimamoto, Hideyuki Konishi, Tsukihisa Yoshida, Mitsuhito Takenoyama, Tokujiro Yano, and Yoshihiko Maehara

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org

ABOUT THE COVER

Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKMT120. For details, see the article by O’Brien and colleagues on page 3507 of this issue.